Currently, many low- and middle-income countries (LMICs) are almost entirely dependent on imports and donations of COVID and other vaccines, contributing to vaccine inequity. Here is an explainer video setting out why we need pharma to ...

MSF authors analyse R&D and regulatory approval of DR-TB drugs bedaquiline and delamanid, and impact on treatment outcomes and access.

In this video, MSF staff working in places where people have been severely affected by COVID-19 speak out about their experiences, and how the lack of access to COVID-19 vaccines has impacted the communities where they work.

BionTech is bypassing the World Health Organization’s (WHO) mRNA vaccine tech transfer hub in South Africa.

The WHO recently released new rapid guidance recommending that children of all ages with drug-resistant tuberculosis (DR-TB) have access to all-oral treatment using the drugs bedaquiline and/or delamanid. However paediatric ...

Sharing mRNA vaccine technology with manufacturers in low- and middle-income countries could offer sustainable, equitable access to COVID-19 vaccines

Next week the Indian government is expected to decide whether it is willing to override patents on two critical tuberculosis (TB) drugs following a court petition filed at the Mumbai High Court by two survivors of TB and activists. MSF ...

This first delivery of COVID-19 vaccine doses by the COVAX Facility is an important start, but it’s very small and late - a massive injection of doses to many more countries is needed. MSF calls on wealthy governments to share their ...

As a highly infectious new strain of COVID-19 spreads through Southern Africa, health workers in Mozambique, Eswatini and Malawi are struggling to treat escalating numbers of patients with little prospect of a vaccine to protect them ...

MSF urges J&J to prioritise initial supply of vaccine to COVAX, if approved

Pharmaceutical corporation AstraZeneca and the University of Oxford announced today that combined data from an interim analysis of a phase 2/3 trial in the United Kingdom (UK) and a phase 3 trial in Brazil suggested that their ...

Pharmaceutical corporation Moderna announced today that preliminary data from a large, ongoing phase 3 trial testing a potential COVID-19 vaccine suggest that the vaccine is 94.5% effective. While this is a promising step, a press ...

Terms of a deal disclosed show that we cannot rely on pharma’s goodwill to do the right thing, even in a pandemic.

Brazilian public research institution Fundação Oswaldo Cruz (Fiocruz) published online the terms of its agreement with pharmaceutical corporation AstraZeneca for the production of a potential future COVID-19 vaccine

As Gavi, the Vaccine Alliance, signs an intent to purchase 200 million doses of vaccine for the COVAX Facility from Sanofi-GlaxoSmithKline (GSK), Médecins Sans Frontières/Doctors Without Borders (MSF) demands transparency from these ...